158 related articles for article (PubMed ID: 17934732)
1. Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients.
Wang H; Cao C; Li B; Chen S; Yin J; Shi J; Ye D; Tao Q; Hu P; Epstein A; Ju D
Cancer Immunol Immunother; 2008 May; 57(5):677-84. PubMed ID: 17934732
[TBL] [Abstract][Full Text] [Related]
2. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer.
Chen S; Yu L; Jiang C; Zhao Y; Sun D; Li S; Liao G; Chen Y; Fu Q; Tao Q; Ye D; Hu P; Khawli LA; Taylor CR; Epstein AL; Ju DW
J Clin Oncol; 2005 Mar; 23(7):1538-47. PubMed ID: 15735129
[TBL] [Abstract][Full Text] [Related]
3. 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer.
Yu L; Ju DW; Chen W; Li T; Xu Z; Jiang C; Chen S; Tao Q; Ye D; Hu P; Khawli LA; Taylor CR; Epstein AL
Cancer Biother Radiopharm; 2006 Feb; 21(1):5-14. PubMed ID: 16480326
[TBL] [Abstract][Full Text] [Related]
4. A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors.
Hornick JL; Sharifi J; Khawli LA; Hu P; Biela BH; Mizokami MM; Yun A; Taylor CR; Epstein AL
Cancer Biother Radiopharm; 1998 Aug; 13(4):255-68. PubMed ID: 10850361
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis treatment of ME-180 human cervical carcinoma model with 131I-labeled TNT-1 monoclonal antibody.
Chen FM; Taylor CR; Epstein AL
Cancer Res; 1989 Aug; 49(16):4578-85. PubMed ID: 2743341
[TBL] [Abstract][Full Text] [Related]
6. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
[TBL] [Abstract][Full Text] [Related]
7. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer.
Street HH; Goris ML; Fisher GA; Wessels BW; Cho C; Hernandez C; Zhu HJ; Zhang Y; Nangiana JS; Shan JS; Roberts K; Knox SJ
Cancer Biother Radiopharm; 2006 Jun; 21(3):243-56. PubMed ID: 16918301
[TBL] [Abstract][Full Text] [Related]
9. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
10. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
11. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab.
Lofgren JA; Dhandapani S; Pennucci JJ; Abbott CM; Mytych DT; Kaliyaperumal A; Swanson SJ; Mullenix MC
J Immunol; 2007 Jun; 178(11):7467-72. PubMed ID: 17513798
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer.
van Zanten-Przybysz I; Molthoff CF; Roos JC; Plaizier MA; Visser GW; Pijpers R; Kenemans P; Verheijen RH
J Nucl Med; 2000 Jul; 41(7):1168-76. PubMed ID: 10914906
[TBL] [Abstract][Full Text] [Related]
13. An affinity column method for determination of the immunoreactivity of 131I-chimeric L6 monoclonal antibody and comparison to in vivo tumor localization.
Jagoda EM; Wen ML; Yost FJ; Schreiber GJ; Tu JI
J Immunol Methods; 1994 Aug; 173(2):191-201. PubMed ID: 8046254
[TBL] [Abstract][Full Text] [Related]
14. Distribution and pharmacokinetics of radiolabeled monoclonal antibody OC 125 after intravenous and intraperitoneal administration in gynecologic tumors.
Haisma HJ; Moseley KR; Battaile A; Griffiths TC; Knapp RC
Am J Obstet Gynecol; 1988 Oct; 159(4):843-8. PubMed ID: 3177533
[TBL] [Abstract][Full Text] [Related]
15. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays.
Buist MR; Kenemans P; van Kamp GJ; Haisma HJ
Cancer Immunol Immunother; 1995 Jan; 40(1):24-30. PubMed ID: 7828165
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial.
Vuillez JP; Kraeber-Bodéré F; Moro D; Bardiès M; Douillard JY; Gautherot E; Rouvier E; Barbet J; Garban F; Moreau P; Chatal JF
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3259s-3267s. PubMed ID: 10541373
[TBL] [Abstract][Full Text] [Related]
17. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
Mittal BB; Zimmer MA; Sathiaseelan V; Benson AB; Mittal RR; Dutta S; Rosen ST; Spies SM; Mettler JM; Groch MW
Cancer; 1996 Nov; 78(9):1861-70. PubMed ID: 8909304
[TBL] [Abstract][Full Text] [Related]
19. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p.
van Zanten-Przybysz I; Molthoff CF; Roos JC; Verheijen RH; van Hof A; Buist MR; Prinssen HM; den Hollander W; Kenemans P
Int J Cancer; 2001 Apr; 92(1):106-14. PubMed ID: 11279613
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
